SCM
XERS icon

Sterling Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Sterling Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.77K Sell
602
-418
-41% -$2.67K ﹤0.01% 2649
2026
Q1 		$5.92K Hold
1,020
– – ﹤0.01% 2658
2025
Q4 		$8.01K Buy
1,020
+648
+174% +$5.1K ﹤0.01% 2712
2025
Q3 		$3.03K Buy
372
+10
+3% +$66 ﹤0.01% 2909
2025
Q2 		$1.69K Buy
362
+220
+155% +$1.01K ﹤0.01% 2956
2025
Q1 		$780 Hold
142
– – ﹤0.01% 2885
2024
Q4 		$481 Hold
142
– – ﹤0.01% 3039
2024
Q3 		$405 Buy
+142
New +$365 ﹤0.01% 2957

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sterling Capital Management's XERS Position: Q2 2026 in Review

Sterling Capital Management reduced its Xeris Biopharma Holdings (XERS) stake by 41% in Q2 2026, selling an estimated $2.67K and leaving 602 shares worth $4.77K. The position accounts for ﹤0.01% of the portfolio, ranked #2649.

Sterling Capital Management first reported a position in XERS in Q3 2024 and has held it in 8 quarters since. The position peaked at $8.01K in Q4 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Sterling Capital Management held 602 shares of Xeris Biopharma Holdings worth $4.77K as of Q2 2026.
  • Sterling Capital Management sold 418 Xeris Biopharma Holdings shares in Q2 2026, an estimated $2.67K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2649 holding.
  • Sterling Capital Management first reported a position in Xeris Biopharma Holdings in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Xeris Biopharma Holdings position peaked at $8.01K in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.